Lawyer: Merck Scrapped Study on Vioxx
ATLANTIC CITY, N.J. (AP) - Merck & Co. scrapped a planned study of the cardiac safety of Vioxx once it knew U.S. regulators were going to tone down their warning about heart risks for patients taking the painkiller, a plaintiff's lawyer argued Friday in a product liability trial.
But Merck's former head of U.S. marketing, David Anstice, testified it was coincidence that the study was canceled in March 2002 as Food and Drug Administration regulators and Merck officials settled on putting a notice about Vioxx cardiac risks in the precautions section of the drug's label -- the fine-print package insert -- rather than in the higher-profile warnings section
· Read The Full Vioxx Article From MSN Money -->
·
Read All Vioxx (Rofecoxib) News Stories -->